1198 NUCLEOTIDE INHIBITOR RESISTANCE SELECTIONS USING GT2A INFECTIOUS VIRUS: PSI-7851 AND GS-6620 SELECT FOR A NOVEL RESISTANCE PATHWAY INCLUDING SUBSTITUTIONS OF M289V/L FOLLOWED BY S282T
G. Cheng,M. Fenaux,E. Mabery,S. Eng,B. Peng,O. Barauskas,L. Lagpacan,D. Jin,M. Hung,X. Liu,J. Perry,J. Feng,A. Ray,W. Delaney,W. Zhong
DOI: https://doi.org/10.1016/s0168-8278(11)61200-2
IF: 25.7
2011-01-01
Journal of Hepatology
Abstract:Background:The forthcoming availability of HCV NS3-protease inhibitors (PI) and the natural tendency of HCV to develop resistance require the monitoring of drug-resistance emergence.The impact of HCV genetic-barrier (defined as number and type of nucleotide-substitutions required to overcome pharmacologicalselective pressure) is still unknown.Because of the extreme HCV variability, we analyzed whether HCV-genotypes have different genetic-barriers for drug-resistance development.Methods: This study analyzed 1476 NS3-protease (188 aminoacids) sequences, retrieved from our laboratory and GenBank, isolated from PI-naive patients infected with HCV-genotypes 1a (N = 621), 1b (N = 462), 2 (N = 58), 3 (N = 247), and 4 (N = 88).Genetic-barrier was calculated as the sum of nucleotide-transitions (score=1) and/or nucleotide-transversions (score=2.5)required for emergence of drug-resistance mutations ( Van de Vijver, 2006).Nineteen key mutations at 7 protease-positions associated with primary telaprevir (TLP) and/or boceprevir (BCP) resistance were analysed (36AML-43SIV-54AVS-55A-155KMTQ-156STV-170AT).Results: Protease amino-acidic sequences showed a very high degree of variability, with only 93/188 (49.5%) conserved aminoacids; 4 residues at resistance-associated positions 43-54-55-156 were fully conserved (variability <1%) among all genotypes.All other drug-resistance positions were found extremely variable.In particular, while valine at position 36 is the wild-type for HCV-1a/b, the resistance mutation V36L is naturally present in 98.3% HCV-2, 100% HCV-3, 70.5% HCV-4.Regardless of HCV-genotype, 9/19 resistance-mutations were found with low genetic-barrier in all HCV-genotypes (V36A-F43S-T54A-V55A-A156TV: score=1, only 1 transition required; F43IV-T54S-A156S: score=2.5,only 1 transversion required).By contrast, nucleotide-heterogeneity among HCV-genotypes correlated with a different genetic-barrier for other drug-resistance mutations.Indeed, V36M had a far lower genetic-barrier in HCV-1a (score=1), than in HCV-2-4 (score=2.5),HCV-1b (score=3.5), .A lower genetic-barrier for R155K was found in HCV-1a-2-3 (score=1) in comparison to genotypes .Conclusions: The stunning degree of HCV genetic variability makes HCV-genotypes, and even sub-genotypes, differently prone to the development of TLP/BCP-resistance mutations.These differences help explaining the experimental/clinical observation that single mutants with low-genetic-barrier (such as V36A-T54A-R155K-A156TV) appear frequently and rapidly in PI-treated patients with genotype-1 (Kieffer, 2007), compared to other mutations with higher genetic-barrier.Overall, this can account for different responsiveness of HCV-genotypes to PI, with important clinical implications in choosing appropriate and individualized regimens.